Axonics, based in Irvine, Calif., is a privately held venture-backed pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/25/14 | $32,600,000 | Series A |
Edmond de Rothschild Investment Partners Legend Capital NeoMed Management | undisclosed |
| 12/21/15 | $38,500,000 | Series B |
Advent Life Sciences Alfred E. Mann Foundation Cormorant Asset Management Edmond de Rothschild Investment Partners Legend Capital NeoMed Management | undisclosed |
| 05/04/17 | $14,500,000 | Series C |
Advent Life Sciences Cormorant Asset Management Edmond de Rothschild Investment Partners Legend Capital NeoMed Management | undisclosed |
| 07/06/17 | $20,500,000 | Series C |
Cormorant Asset Management Gilde Healthcare Partners | undisclosed |
| 04/03/18 | $40,100,000 |
Gilde Healthcare Partners Longitude Capital  Silicon Valley Bank | undisclosed |
